These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 8420806)

  • 1. Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients.
    Schneider DJ; Nordt TK; Sobel BE
    Diabetes; 1993 Jan; 42(1):1-7. PubMed ID: 8420806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential risk factor for vascular disease.
    Nordt TK; Schneider DJ; Sobel BE
    Circulation; 1994 Jan; 89(1):321-30. PubMed ID: 8281664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrinogen, fibrinolysis and diabetes mellitus: a comment.
    Vague P; Juhan-Vague I
    Diabetologia; 1997 Jun; 40(6):738-40. PubMed ID: 9222657
    [No Abstract]   [Full Text] [Related]  

  • 4. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients.
    McGill JB; Schneider DJ; Arfken CL; Lucore CL; Sobel BE
    Diabetes; 1994 Jan; 43(1):104-9. PubMed ID: 8262307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diminished fibrinolysis and thrombosis: clinical implications for accelerated atherosclerosis.
    Fujii S; Goto D; Zaman T; Ishimori N; Watano K; Kaneko T; Okada H; Makiguchi M; Nakagawa T; Kitabatake A
    J Atheroscler Thromb; 1998; 5(2):76-81. PubMed ID: 10855561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
    Kruszynska YT; Yu JG; Olefsky JM; Sobel BE
    Diabetes; 2000 Apr; 49(4):633-9. PubMed ID: 10871202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrin(ogen) and diabetes mellitus: don't forget fibrinolysis.
    Morale M; De Negri F; Carmassi F
    Diabetologia; 1997 Jun; 40(6):735-7. PubMed ID: 9222656
    [No Abstract]   [Full Text] [Related]  

  • 8. Insulin resistance and thrombosis: a cardiologist's view.
    Sobel BE
    Am J Cardiol; 1999 Jul; 84(1A):37J-41J. PubMed ID: 10418858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased plasminogen activator inhibitor type 1 in coronary artery atherectomy specimens from type 2 diabetic compared with nondiabetic patients: a potential factor predisposing to thrombosis and its persistence.
    Sobel BE; Woodcock-Mitchell J; Schneider DJ; Holt RE; Marutsuka K; Gold H
    Circulation; 1998 Jun; 97(22):2213-21. PubMed ID: 9631870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease.
    Panahloo A; Yudkin JS
    Coron Artery Dis; 1996 Oct; 7(10):723-31. PubMed ID: 8970763
    [No Abstract]   [Full Text] [Related]  

  • 11. [Theoretical aspects of the relationship between diabetic macroangiopathy and hyperinsulinism].
    Leutenegger M
    Presse Med; 1992 Sep; 21(28):1324-9. PubMed ID: 1438101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects.
    Pandolfi A; Cetrullo D; Polishuck R; Alberta MM; Calafiore A; Pellegrini G; Vitacolonna E; Capani F; Consoli A
    Arterioscler Thromb Vasc Biol; 2001 Aug; 21(8):1378-82. PubMed ID: 11498469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Endothelium and endogenous fibrinolysis].
    Nordt TK; Bode C
    Z Kardiol; 2000 Mar; 89(3):219-26. PubMed ID: 10798278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
    Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling.
    Herlihy OM; Barrow BA; Grant PJ; Levy JC
    Diabetologia; 2002 May; 45(5):635-41. PubMed ID: 12107743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes.
    Trost S; Pratley R; Sobel B
    Curr Diab Rep; 2006 Feb; 6(1):47-54. PubMed ID: 16522281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diminished fibrinolysis in diabetes mellitus and its implication for diabetic vascular disease.
    Panahloo A; Yudkin JS
    J Cardiovasc Risk; 1997 Apr; 4(2):91-9. PubMed ID: 9304490
    [No Abstract]   [Full Text] [Related]  

  • 18. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis.
    Nordt TK; Klassen KJ; Schneider DJ; Sobel BE
    Arterioscler Thromb; 1993 Dec; 13(12):1822-8. PubMed ID: 8241103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).
    Festa A; D'Agostino R; Mykkänen L; Tracy RP; Zaccaro DJ; Hales CN; Haffner SM
    Arterioscler Thromb Vasc Biol; 1999 Mar; 19(3):562-8. PubMed ID: 10073958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute hyperglycemia and acute hyperinsulinemia decrease plasma fibrinolytic activity and increase plasminogen activator inhibitor type 1 in the rat.
    Pandolfi A; Giaccari A; Cilli C; Alberta MM; Morviducci L; De Filippis EA; Buongiorno A; Pellegrini G; Capani F; Consoli A
    Acta Diabetol; 2001; 38(2):71-6. PubMed ID: 11757804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.